Form 13-F position report

ENLIVEN THERAPEUTICS INC

Reported by ORBIMED ADVISORS LLC

ELVN CUSIP 29337E102 Manager CIK 0001055951

Reported 6,776,632 shares, unchanged from the prior quarter.

Reported value -9.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 5.67% This manager · Q3 2026
Shares 6,776,632 Quarter-end amount reported
Reported value $310,640,811 Fair value at quarter end
Consecutive quarters held 15 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-03-31 197017065
2023-06-30 183656079
2023-09-30 122917297
2023-12-31 124536998
2024-03-31 158280765
2024-06-30 186014403
2024-09-30 203286601
2024-12-31 179089605
2025-03-31 156643708
2025-06-30 159668332
2025-09-30 162931743
2025-12-31 122576885
2026-03-31 312013890
2026-06-30 343914074
2026-09-30 310640811

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for ENLIVEN THERAPEUTICS INC held by ORBIMED ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 6,776,632 0 (0.0%) 5.67% $310,640,811 2026-11-16
Q2 2026 Reduced 6,776,632 -1,182,906 (-14.9%) 6.41% $343,914,074 2026-08-14
Q1 2026 Unchanged 7,959,538 0 (0.0%) 6.21% $312,013,890 2026-05-15
Q4 2025 Unchanged 7,959,538 0 (0.0%) 2.51% $122,576,885 2026-02-17
Q3 2025 Unchanged 7,959,538 0 (0.0%) 3.84% $162,931,743 2025-11-14
Q2 2025 Unchanged 7,959,538 0 (0.0%) 4.0% $159,668,332 2025-08-14
Q1 2025 Unchanged 7,959,538 0 (0.0%) 3.75% $156,643,708 2025-05-15
Q4 2024 Unchanged 7,959,538 0 (0.0%) 3.7% $179,089,605 2025-02-14
Q3 2024 Unchanged 7,959,538 0 (0.0%) 3.71% $203,286,601 2024-11-14
Q2 2024 Reduced 7,959,538 -1,038,800 (-11.5%) 3.7% $186,014,403 2024-08-14
Q1 2024 Unchanged 8,998,338 0 (0.0%) 2.92% $158,280,765 2024-05-15
Q4 2023 Unchanged 8,998,338 0 (0.0%) 2.51% $124,536,998 2024-02-14
Q3 2023 Unchanged 8,998,338 0 (0.0%) 2.64% $122,917,297 2023-11-14
Q2 2023 Added 8,998,338 +2,125 (0.0%) 3.37% $183,656,079 2023-08-14
Q1 2023 New 8,996,213 +8,996,213 (0.0%) 3.91% $197,017,065 2023-05-15

Who else reported the position

245 managers reported ENLIVEN THERAPEUTICS INC for Q3 2026.

Managers reporting ENLIVEN THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 10,827,727 +802,710 0.02% $496,343,006 15 qtrs
ORBIMED ADVISORS LLC This report Unchanged 6,776,632 0 5.67% $310,640,811 15 qtrs
Polar Capital Holdings Plc Reduced 6,425,271 -5,365 0.71% $294,534,423 10 qtrs
BlackRock Inc Added 5,711,966 +1,352,262 < 0.01% $261,836,522 9 qtrs
COMMODORE CAPITAL LP Unchanged 3,275,000 0 11.63% $150,126,000 15 qtrs
Vestal Point Capital LP Reduced 3,225,000 -775,000 3.82% $147,834,000 6 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 2,893,109 +324,107 < 0.01% $132,620,117 3 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 2,350,207 -553,700 0.01% $107,735,000 10 qtrs
Fairmount Funds Management LLC Unchanged 1,855,644 0 5.33% $85,062,721 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,708,920 +301,718 < 0.01% $78,351,951 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
6,776,632
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.